{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02997709",
            "orgStudyIdInfo": {
                "id": "20150452"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2019-08552",
                    "type": "REGISTRY",
                    "domain": "NCI Clinical Trials Reporting Program (NCI CTRP)"
                }
            ],
            "organization": {
                "fullName": "University of Miami",
                "class": "OTHER"
            },
            "briefTitle": "Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients",
            "officialTitle": "Collection and Measurement of Blood and Imaging Biomarkers in Patients Undergoing Standard Primary and Postoperative Radiotherapy for Prostatic Neoplasms - The Miami CoMBINe Trial",
            "acronym": "COMBINE",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "collection-and-measurement-of-biomarkers-in-prostate-cancer-radiotherapy-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-06-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-12-15",
            "studyFirstSubmitQcDate": "2016-12-15",
            "studyFirstPostDateStruct": {
                "date": "2016-12-20",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-01-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Alan Pollack, MD, PhD",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Miami"
            },
            "leadSponsor": {
                "name": "University of Miami",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Bankhead-Coley Florida Biomedical Research Program",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET imaging characteristics and changes are related to the expression of genes in the cancer tissue obtained before treatment from prostate biopsy or a prior prostatectomy before treatment. 4) How the response of prostate cancer treatment relates to the imaging and CTC changes."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ],
            "keywords": [
                "Circulating Tumor Cells",
                "CTCs",
                "Androgen Deprivation Therapy",
                "ADT"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "Blood will be collected pre-RT and in post-RT follow-up for research. Plasma and serum, as well as red cells and lymphocytes (buffy coat) will be collected. The procedures will evolve with new developments, such as the ability to isolate viable CTCs for cell culture and gene expression analyses. Excess blood that is not processed for CTC or biomarkers will be stored for future research.\n\nGenomic studies, including genome-wide association studies (GWAS), will examine associations with health conditions are planned. Gene expression from mpMRI-defined high risk tumor regions will be related to pathologic parameters and RT response. Using a 1.4M marker oligonucleotide microarray that is essentially a whole transcriptome assay, selected pathways will be examined in pre-Tx biopsies."
            },
            "enrollmentInfo": {
                "count": 144,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Radiation Therapy Group",
                    "description": "Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated"
                },
                {
                    "label": "Prostatectomy Group",
                    "description": "Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated"
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Comparison of Pre- and Post-Treatment Quantitative Imaging Parameters to Changes in Circulating Tumor Cells Over Time in Study Participants.",
                    "description": "Pre-Treatment and Post-Treatment quantitative imaging parameters will be associated with circulating tumor cell (CTC) changes over time in prostate cancer (PCa) patients who receive treatment with RT \u00b1 androgen deprivation therapy (ADT) or prostatectomy per standard of care. CTC and quantitative imaging changes will be determined at each of the planned research acquisition time points (8 days prior to completion of radiation therapy (RT), 3 months post-RT, 9 months post-RT, and 2-2.5 years post-treatment) comparing to the Baseline.",
                    "timeFrame": "Baseline, within 8 Days Prior to End of RT, 3 months Post-RT, 9 months and 2-2.5 Years Post-RT"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Relationship of CTC changes and/or quantitative imaging parameter changes to patient outcome (biochemical and clinical disease failure).",
                    "description": "CTC changes between baseline and 2-2.5 years will be compared with 2-2.5 year biopsy positivity status (positive vs. negative) for patients whose baseline and 2-2.5 year biopsy samples are available. CTC changes from two different time points will be tested for significance using t-test by 2-2.5 year biopsy positivity status. Correlation structures between CTC and imaging parameters will be analyzed using linear mixed-effect model by 2-2.5 year biopsy positivity status.",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Relationship of Androgen Deprivation Therapy (ADT) status to quantitative imaging features and/or CTC levels in patients",
                    "description": "Change of CTC and imaging parameters at a specific time point from baseline will be compared by ADT status (yes vs. no) using t-test. Correlation structure between CTC and imaging parameters will be analyzed using linear mixed-effect model by ADT status.",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Relationship of quantitative imaging characteristics and/or CTC changes with other tissue biomarkers obtained from the pre-treatment MRI ultrasound (US) fusion guided prostate biopsy or prostatectomy tissue in those treated primarily.",
                    "description": "Gene expression data obtained at baseline will be analyzed in order to investigate the relationship between the gene expression and the following: CTCs, mpMRI imaging parameters, histopathological tumor parameters, and biochemical/clinical failure.\n\nCTC changes between baseline and 2-2.5 years will be compared with 2-2.5 year biopsy positivity status (positive vs. negative) for patients whose baseline and 2-2.5 year biopsy samples are available. CTC changes from two different time points will be tested for significance using t-test by 2-2.5 year biopsy positivity status. Changes in gene expression and imaging parameters will be analyzed in the same manner. Correlation structures between CTC and imaging parameters; CTC and gene expression; and imaging parameters and gene expression will be analyzed using linear mixed-effect model by 2-2.5 year biopsy positivity status.",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Comparison of changes in CTCs to endpoint prostate research biopsy status.",
                    "description": "In patients who have undergone the MRI-US fusion guided biopsy (MUFgBx) at 2-2.5 years after all planned treatment, to investigate the relationship of circulating tumor cell (CTC) changes with the endpoint of research prostate biopsy status (only for those who are treated primarily with RT, who are not on indefinite ADT and who agree to this prostate early \"endpoint\" biopsy).",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Comparison of changes in quantitative imaging characteristics to endpoint prostate research biopsy status.",
                    "description": "In patients who have undergone the MRI-US fusion guided biopsy (MUFgBx) at 2-2.5 years after all planned treatment, to investigate the relationship of quantitative imaging characteristics with the endpoint of research prostate biopsy status (only for those who are treated primarily with RT, who are not on indefinite ADT and who agree to this prostate early \"endpoint\" biopsy).",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Comparison of changes in gene expression patterns to endpoint prostate research biopsy status.",
                    "description": "In patients who have undergone the MRI-US fusion guided biopsy (MUFgBx) at 2-2.5 years after all planned treatment, to investigate the relationship of pretreatment biopsy tissue gene expression patterns with the research endpoint of prostate biopsy status (only for those who are treated primarily with RT, who are not on indefinite ADT and who agree to this prostate early \"endpoint\" biopsy).",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                },
                {
                    "measure": "Determination of the added value of PET/CT using newer tracers to MRI",
                    "description": "PET/CT using newer tracers (fluciclovine, prostate-specific membrane antigen (PSMA), or Choline) to MRI may add value in the above secondary analyses. The investigators hypothesize that targeted PET agents will enhance the rate of accuracy of mpMRI in establishing high risk areas in the prostate, prostate bed, and pelvic lymph nodes, as well as provide unique information on early metastatic disease.",
                    "timeFrame": "Between Baseline and 2-2.5 Years Post-RT"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Pathologic confirmation of prostate cancer.\n2. Any T-stage.\n3. By imaging or clinical criteria, any patient with disease staging of N0/N1 and M0/M1.\n\n   * Patients with metastatic disease are encouraged to participate.\n4. Any Gleason Score will be eligible.\n5. Androgen deprivation therapy (ADT) is at the discretion of the treating physician, but must be declared as none, short-term, long-term, or extended prior to enrollment. The length is calculated from the LHRH (agonist injection). If ADT is planned (based on treating physician preference), the following restrictions apply:\n\n   * Short term ADT is defined as \u2264 7 months;\n   * Long term ADT is defined as \\> 7 months and \u2264 36 months;\n   * Extended ADT is defined as \\>36 months (e.g., M1 patients).\n6. Prostate-specific antigen (PSA) \u2264100 ng/mL within (+/-) 4 months of signing of consent. If PSA was above 100 and drops to \\<100 with antibiotics, this is acceptable for enrollment.\n7. No previous pelvic radiotherapy.\n8. The ability to understand and the willingness to sign a written informed consent document\n9. Zubrod performance status \u2264 2 (Karnofsky or ECOG performance status may be used to estimate Zubrod):\n10. Age \u2265 30 at signing of consent.\n11. Subjects must be planned to receive radiation therapy or to undergo prostatectomy.\n12. Subjects treated primarily with RT are recommended to have had an MUFgBx prior to radiation treatment.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Adult men with a prostate cancer diagnosis.",
            "minimumAge": "30 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Adult men with a prostate cancer diagnosis undergoing standard of care treatment at the University of Miami.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pavel Noa Hechevarria",
                    "role": "CONTACT",
                    "phone": "305-243-1036",
                    "email": "pavel.noa@med.miami.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alan Pollack, MD, PhD",
                    "affiliation": "University of Miami",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pavel Noa Hechevarria",
                            "role": "CONTACT",
                            "phone": "305-243-1036",
                            "email": "pavel.noa@med.miami.edu"
                        },
                        {
                            "name": "Alan Pollack, MD, Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Matthew Abramowitz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Radka Stoyanova, Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Alan Dal Pra, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12305",
                    "name": "Neoplastic Cells, Circulating",
                    "relevance": "LOW"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}